Generating drug specific monoclonal antibodies against TTHX1114, an engineered mutant human FGF1
Ended Awarded Last action
- Contract number
- 75N95019F00088
- Awardee
-
A&G Pharmaceutical, Inc. UEI SN6SWFABJXL1
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $50,209
Award facts
- Opportunity
-
- N01TR182006 Solicitation number
- Reagent Generation for Bioanalytical Method Development for Biologics Award Notice · Posted Oct 13, 2017
- Contract value 100% obligated
- $50,208.55 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- National Center for Advancing Translational Sciences National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Basic Research
- Pricing
- Firm Fixed Price
- Place of performance
- Columbia, MD 21045, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | -$54,639 | |
| Original award | $104,848 |
About this award
The U.S. Department of Health and Human Services, National Institutes of Health, National Center for Advancing Translational Sciences awarded a firm-fixed price delivery order contract to A&G Pharmaceutical, Inc., doing business as Precision Antibody, to generate drug-specific monoclonal antibodies against TTHX1114, an engineered mutant human FGF1. The $50,208.55 contract has a completion date of June 30, 2020 and does not have a set-aside designation. Precision Antibody is a for-profit manufacturer of goods that has provided similar services to NIH, including a $100 million Blanket Purchase Agreement to supply monoclonal antibodies, cell lines, labeled antibodies, polyclonal antibodies, and peptide synthesis to support biomedical research programs across NIH institutes and the Department of Agriculture.
Quick answers
Who was awarded contract 75N95019F00088?
75N95019F00088 was awarded to A&G Pharmaceutical, Inc. by National Institute on Drug Abuse (National Institutes of Health) on September 24, 2019.
How much is contract 75N95019F00088 worth?
The government has obligated $50,209 on 75N95019F00088.
Which agency awarded contract 75N95019F00088?
National Institute on Drug Abuse (National Institutes of Health) awarded 75N95019F00088, with funding from National Center for Advancing Translational Sciences (National Institutes of Health).
Is contract 75N95019F00088 an order under another contract?
Yes. 75N95019F00088 is a delivery order under 75N95018D00010, an indefinite delivery contract.
Was contract 75N95019F00088 competed?
The extent of competition for 75N95019F00088 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award